Proprietary AI analyst is now available

HBM Healthcare Investments Valuation Multiples

Discover HBM Healthcare Investments' revenue and EBITDA valuation multiples and investment history, alongside public comparables like Antin Infrastructure Partners, FIBRA Macquarie, GIMV, L1 Long Short Fund and more.

HBM Healthcare Investments Overview

About HBM Healthcare Investments

HBM Healthcare Investments Ltd is a Switzerland-based holding company. The firm actively invests in the human medicine, biotechnology, medical technology, and diagnostics sectors and related areas. The company holds and manages an international portfolio of companies.


Founded

2001

HQ

Switzerland

Employees

1

Financials (LTM)

Revenue: $102M
Net Income: $347M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

HBM Healthcare Investments Financials

HBM Healthcare Investments reported last 12-month revenue of $102M.

In the same LTM period, HBM Healthcare Investments generated $347M in net income.

Revenue (LTM)


HBM Healthcare Investments P&L

In the most recent fiscal year, HBM Healthcare Investments reported revenue of $347M and net income of $347M.

HBM Healthcare Investments is profitable as of last fiscal year, with net margin of 100%.

See analyst estimates for HBM Healthcare Investments
LTMLast FY202320242025202620272028
Revenue$102M$347M($44M)$20M$267M
Net Profit$347M$347M($47M)$17M$264M
Net Margin340%100%106%85%99%
Net Debt-$119M---

Financial data powered by Morningstar, Inc.

HBM Healthcare Investments Stock Performance

HBM Healthcare Investments has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


HBM Healthcare Investments' stock price is $296.45.

HBM Healthcare Investments share price decreased by 2.7% in the last 30 days, and increased by 36.0% in the last year.

HBM Healthcare Investments has an EPS (earnings per share) of $52.53.

See more trading valuation data for HBM Healthcare Investments
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B0.7%-2.7%2.9%36.0%$52.53

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

HBM Healthcare Investments Valuation Multiples

HBM Healthcare Investments trades at 20.4x EV/Revenue multiple.

See NTM and 2027E valuation multiples for HBM Healthcare Investments

EV / Revenue (LTM)


HBM Healthcare Investments Financial Valuation Multiples

As of June 5, 2026, HBM Healthcare Investments has market cap of $2B and EV of $2B.

HBM Healthcare Investments has a P/E ratio of 5.6x.

LTMLast FY202320242025202620272028
EV/Revenue20.4x6.0x(46.9x)102.3x7.8x
P/E5.6x5.6x(41.5x)113.7x7.4x
EV/FCF-n/mn/mn/mn/m

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified HBM Healthcare Investments Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

HBM Healthcare Investments Margins & Growth Rates

In the most recent fiscal year, HBM Healthcare Investments reported net margin of 100%.

See estimated margins and future growth rates for HBM Healthcare Investments

HBM Healthcare Investments Margins

Last FY202420252026202720282029
Net Margin100%85%99%99%
FCF Margin(1%)(14%)(1%)(1%)

HBM Healthcare Investments Growth Rates

23/2424/2525/2626/2727/2828/29
Revenue Growth(146%)1209%30%
Net Profit Growth(136%)1429%30%
FCF Growth37%19%3%

Data powered by FactSet, Inc. and Morningstar, Inc.

HBM Healthcare Investments Operational KPIs

HBM Healthcare Investments' revenue per employee in the last FY averaged $346.9M, while opex per employee averaged $3.3M for the same period.

Access forward-looking KPIs for HBM Healthcare Investments
Last FY202320242025202620272028
Revenue per Employee$346.9M---
Opex per Employee$3.3M---
G&A Expenses to Revenue1%(5%)13%1%
Opex to Revenue1%(6%)15%1%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

HBM Healthcare Investments Competitors

HBM Healthcare Investments competitors include Antin Infrastructure Partners, FIBRA Macquarie, GIMV, L1 Long Short Fund, Tri-Continental, L1 Group, AFP ProVida, Patria Investments, Vukile Property Fund and Goodman New Zealand.

Most HBM Healthcare Investments public comparables operate across Asset Management.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Antin Infrastructure Partners4.7x4.6x8.1x8.6x
FIBRA Macquarie10.4x10.3x13.7x13.5x
GIMV5.9x---
L1 Long Short Fund10.0x---
Tri-Continental7.5x---
L1 Group17.4x5.4x74.6x7.5x
AFP ProVida4.7x-7.2x-
Patria Investments5.1x5.0x10.0x9.2x

This data is available for Pro users. Sign up to see all HBM Healthcare Investments competitors and their valuation data.

Start Free Trial

Investments by HBM Healthcare Investments

HBM Healthcare Investments has invested in 79 companies to date.

Latest investment by HBM Healthcare Investments was on May 5th 2026. HBM Healthcare Investments invested in CellCentric in their $220M Series D round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by HBM Healthcare Investments

CellCentric
SnapNurse
Jixing Pharmaceuticals
Electra Therapeutics
Description
CellCentric is a Cambridge-headquartered clinical-stage biotechnology company developing p300/CBP inhibitors for cancer therapy. Its lead candidate, inobrodib, entered Phase II trials for multiple myeloma and NRAS-mutant melanoma in 2023. The oral drug targets bromodomain proteins in solid tumors like non-small cell lung cancer. Founded in 2016, CellCentric collaborates with the University of Cambridge on combination regimens with PD-1 inhibitors.
SnapNurse is a per diem staffing platform matching nurses and clinicians with hospitals using Instastaff AI algorithms. Tampa-headquartered since 2018, it handles credentialing, scheduling, and payments for shifts in Florida facilities. SnapNurse serves over 100 healthcare providers, supporting specialties like ICU and ER with mobile booking and timecard approvals.
Jixing Pharmaceuticals is a Shanghai-headquartered biotechnology firm developing therapeutics for cardiovascular and ophthalmic conditions. Its pipeline features JS201 for hypertrophic cardiomyopathy, JS102 for heart failure, JS301 for presbyopia and dry eye, and JS401 for hypertension, with multiple candidates in Phase 2 and 3 trials. Founded in 2019, the company has secured over $300 million in funding and collaborates with global pharma partners.
Electra Therapeutics is a biotechnology company developing SIRP-targeting antibodies to deplete pathological immune cells in hyperinflammatory diseases. Headquartered in New York City since 2020, its lead candidate ELA026 advances in Phase 2 trials for secondary hemophagocytic lymphohistiocytosis with orphan drug designation from FDA and EMA. ELA822 targets additional immunology indications, backed by $100 million in funding from investors including ARCH Venture Partners and Takeda.
HQ CountryUnited KingdomUnited StatesChinaUnited States
HQ City
Cambridge
Atlanta, GA
Shanghai
San Francisco, CA
Deal Date5 May 202628 Apr 202622 Jan 202622 Oct 2025
RoundSeries DSeries ASeries DSeries C
Raised$220Mundisclosed$287M$183M
InvestorsAvego Bioscience Capital; BrightEdge (American Cancer Society VC unit); Fidelity; Forbion Capital Partners; HBM Healthcare Investments; Pfizer; RA Capital Management; Sofinnova Partners; Venrock Healthcare Capital PartnersData Point Capital; HBM Healthcare Investments; Infinitum Asset Management; Suvretta Capital ManagementAdage Capital Management; HBM Healthcare Investments; Hengdian Group; Invus; RA Capital Management; RTW Investments; SilverArc Capital; SR One; TCG CrossoverBlue Owl; Cormorant Asset Management; EQT; HBM Healthcare Investments; Mubadala Capital; New Leaf Venture Partners; Nextech Invest; OrbiMed; RA Capital Management; Redmile Group; Sanofi; Westlake Village BioPartners
Valuation$900Mundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all HBM Healthcare Investments investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About HBM Healthcare Investments

When was HBM Healthcare Investments founded?HBM Healthcare Investments was founded in 2001.
Where is HBM Healthcare Investments headquartered?HBM Healthcare Investments is headquartered in Switzerland.
How many employees does HBM Healthcare Investments have?As of today, HBM Healthcare Investments has over 1 employees.
Is HBM Healthcare Investments publicly listed?Yes, HBM Healthcare Investments is a public company listed on SIX Swiss Exchange.
What is the stock symbol of HBM Healthcare Investments?HBM Healthcare Investments trades under HBMN ticker.
Who are competitors of HBM Healthcare Investments?HBM Healthcare Investments main competitors include Antin Infrastructure Partners, FIBRA Macquarie, GIMV, L1 Long Short Fund, Tri-Continental, L1 Group, AFP ProVida, Patria Investments, Vukile Property Fund, Goodman New Zealand.
What is the current market cap of HBM Healthcare Investments?HBM Healthcare Investments' current market cap is $2B.
What is the current revenue of HBM Healthcare Investments?HBM Healthcare Investments' last 12 months revenue is $102M.
What is the current EV/Revenue multiple of HBM Healthcare Investments?Current revenue multiple of HBM Healthcare Investments is 20.4x.
What is the current net income of HBM Healthcare Investments?HBM Healthcare Investments' last 12 months net income is $347M.
How many companies HBM Healthcare Investments has acquired to date?HBM Healthcare Investments hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies HBM Healthcare Investments has invested to date?As of June 2026, HBM Healthcare Investments has invested in 79 companies.
What was the last HBM Healthcare Investments investment?On 5th May 2026 HBM Healthcare Investments invested in CellCentric, participating in a $220M Series D round at $900M valuation, alongside Avego Bioscience Capital, BrightEdge (American Cancer Society VC unit), Fidelity, Forbion Capital Partners, Pfizer, RA Capital Management, Sofinnova Partners, and Venrock Healthcare Capital Partners.
In what companies HBM Healthcare Investments invested in?HBM Healthcare Investments invested in Everest Medicines, Jixing Pharmaceuticals, Harmony Biosciences, Alumis, CellCentric, Odyssey Therapeutics, NiKang Therapeutics, Ambrx, Upstream Bio, Valo Health, Electra Therapeutics, Bluejay Therapeutics, Nuance Biotech, SK Biopharmaceuticals, Ignis Therapeutics, FogPharma, Karius, IO Biotech, VISEN Pharmaceuticals, Jianke, and 59 other companies.

See public comps similar to HBM Healthcare Investments

Lists including HBM Healthcare Investments

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial